Qualifying Condition

Medical Marijuana for Multiple Sclerosis in Florida

An autoimmune disease affecting the central nervous system and causing spasticity and pain.

Board-Certified Physician · OMMU Certified · Boca Raton, FL

Overview

Multiple Sclerosis (MS) is a chronic autoimmune disease in which the body attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord. This demyelination disrupts communication between the brain and the rest of the body, causing a wide range of symptoms including dizziness, fatigue, coordination problems, muscle spasms and stiffness, difficulty eating, slurred speech, tremors, tingling, pain, and balance impairment. Over 2.3 million people worldwide are affected, with women approximately three times more likely to develop the condition than men.

MS follows several clinical courses: 85% of patients have relapsing-remitting MS (alternating between attacks and remissions), while others experience progressive forms where symptoms continuously worsen. There is currently no cure. Conventional treatments including corticosteroids and immunosuppressive drugs attempt to slow progression but carry serious side effects — increased infection vulnerability, fluid retention, mood swings, elevated blood pressure, and insomnia. Disease-modifying therapies (DMTs) have improved long-term outcomes but do not adequately address the day-to-day symptom burden that most impacts quality of life.

Florida explicitly lists Multiple Sclerosis as a qualifying condition under Statute 381.986. MS has one of the strongest clinical evidence bases for medical cannabis efficacy among all neurological conditions — strong enough that nabiximols (Sativex), a THC:CBD oromucosal spray, has been approved in over 25 countries specifically for MS spasticity.

How Medical Cannabis May Help

Multiple Sclerosis has one of the strongest evidence bases for medical cannabis of any condition. The landmark Cannabinoids in Multiple Sclerosis (CAMS) study (Zajicek et al., The Lancet, 2003) — a large randomized trial of 630 patients across 33 UK centres — found that 61% of patients in the cannabis treatment group reported improvement in spasticity. Patient-reported spasticity and pain significantly improved (P=0.003), and sleep quality also improved compared to placebo over the 15-week study period. A Phase 3 trial (Novotna et al., European Journal of Neurology, 2011) tested nabiximols (Sativex) as add-on therapy for refractory MS spasticity and found significant improvement in spasticity scores (P=0.026). Approximately 40% of patients who showed early response achieved noticeable, sustained improvement lasting months to years. A 2024 meta-analysis of nine clinical trials involving 2,544 MS patients (Azadvari et al., Multiple Sclerosis and Related Disorders) confirmed that cannabis-based therapies are associated with clinically meaningful improvements in MS-related spasticity. Cannabinoids produce a powerful anti-inflammatory effect through CB2 receptor activation on immune cells, potentially slowing demyelination. CB1 receptors, densely expressed in motor control areas of the brain, reduce excitatory neurotransmitter release when activated, decreasing muscle hyperexcitability and spasticity. Cannabis also provides meaningful relief from neuropathic pain, bladder dysfunction, and insomnia. Treatment can be administered through vaporization, edibles, topical applications, and other methods, with side effects that are mild compared to conventional immunosuppressive drugs. Dr. Stratt will work with each patient to determine the optimal strain and delivery method based on their specific MS type and symptom profile.

Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.

What to Bring to Your Appointment

Bring a valid Florida ID and neurology records confirming MS diagnosis (including MRI reports documenting lesion burden), current medication list, and documentation of specific symptoms.

Frequently Asked Questions

Can medical marijuana help with MS spasticity and muscle stiffness in Florida?

Yes — MS has one of the strongest evidence bases for cannabis efficacy. The landmark CAMS study of 630 patients found 61% reported improvement in spasticity. Nabiximols (a THC:CBD spray) is approved in over 25 countries for MS spasticity. Florida lists MS as a qualifying condition, and most patients notice improvement within 4–8 weeks of consistent use.

Is medical marijuana better than my current MS medications for spasticity?

Cannabis is typically used as add-on therapy when standard antispasticity drugs (baclofen, tizanidine) provide incomplete relief. The Novotna 2011 trial showed about 40% of patients achieve sustained improvement when nabiximols are added to existing treatment. Dr. Stratt can work with your neurologist to integrate cannabis into your treatment plan.

Does medical marijuana help with MS-related pain and sleep problems?

Yes. The CAMS study found statistically significant improvements in both pain and sleep quality (P=0.003). Cannabis addresses multiple symptoms simultaneously — spasticity, neuropathic pain, and insomnia — which is a significant advantage over single-symptom medications. Many Florida MS patients report improved sleep as one of the earliest and most consistent benefits.

Medical Marijuana for Muscle Spasms 3 min read · Conditions

The Endocannabinoid System Explained: How Medical Cannabis Works 4 min read · Research & Science

Indica vs. Sativa: Which Is Better for Pain Management? 7 min read · Research & Science